Australia's most trusted
source of pharma news
Wednesday, 04 February 2026
Posted 4 February 2026 AM
Novo Nordisk is spruiking new trial data showing its next-generation obesity treatment CagriSema has significantly outperformed semaglutide in key metrics.
The head-to-head REIMAGINE 2 trial pitted CagriSema, a combination of semaglutide and novel amylin receptor agonist cagrilintide, against the basis of its current obesity and diabetes portfolio, semaglutide alone.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.